You are here

  • Home
  • Archive
  • Volume 12, Issue 7
  • Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells

Article info

Article menu
Immune cell therapies and immune cell engineering
Original research
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells

Authors

  • Anders W Matson Graduate Program in Comparative and Molecular Biosciences, University of Minnesota, Saint Paul, Minnesota, USA PubMed articlesGoogle scholar articles
  • Rob Hullsiek Graduate Program in Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Kate J Dixon Department of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Sam Wang Department of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Anders J Lindstedt Graduate Program in Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, Minnesota, USAMedical Scientist Training Program, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Ryan R Friess Graduate Program in Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Shee Kwan Phung Graduate Program in Comparative and Molecular Biosciences, University of Minnesota, Saint Paul, Minnesota, USA PubMed articlesGoogle scholar articles
  • Tanya S Freedman Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USAMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USADepartment of Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Martin Felices Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Emily N Truckenbrod Department of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Jianming Wu Department of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Jeffrey S Miller Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USAMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USADepartment of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Bruce Walcheck Department of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, Minnesota, USACenter for Immunology, University of Minnesota, Minneapolis, Minnesota, USAMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles

Citation

Matson AW, Hullsiek R, Dixon KJ, et al
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells
Journal for ImmunoTherapy of Cancer 2024;12:e008959. doi: 10.1136/jitc-2024-008959
Online issue publication 
July 24, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.